3 Indian pharma cos face EU anti-trust probe

Font Size

Print

Feedback

Email

Discuss

Related Articles

Sun Pharma’s net dips 11% on US salesEU anti-trust raid on Ranbaxy France unit

Mumbai: Indian pharmaceutical companies Lupin Ltd, Matrix Laboratories and Unichem Laboratories have come under the European Union Competition Commission scanner for an alleged understanding with global players that could have led to delay in launching a generic version of a much-sought-after drug in the European market.

According to an anti-trust report dated July 8, the European Union alleged that firms such as Teva, Lupin, Matrix and Unichem' arm Niche Generics have entered into agreements that might have hindered the market entry of a generic version of Servier's perindopril, a hypertension medication. In April 2007, Lupin had sold certain patent and intellectual property rights of perindopril to French firm Laboratories Servier for Rs 115.31 crore (euro 20 million).

On Wednesday, the shares of Lupin went down 3% on BSE, while Unichem shares went down 2.7%.

A Lupin spokesperson said, "Lupin confirms that it is currently assisting the European Commission with its investigation in relation to the supply of perindopril in the EU. The investigation is still at an early stage and the commission has confirmed that the publication of its statement does not imply it has proof of an infringement of the competition rules. We feel confident about our position and are working with the European Commission to a resolution on the matter."

BK Sharma, executive director, Unichem, said there was nothing wrong with its deal with Servier. "Niche Generics had entered the deal in 2005 with Matrix for marketing the finished product, perindopril, and later made an out-of-court settlement among three of us. We have responded to the EU refuting the allegations raised against Niche Generics."

The probes come as the commission said in a report that companies use a variety of techniques to delay the introduction of generics "for as long as possible." The commission, the EU's executive arm, said it would continue to probe whether the use of patents to delay generics violates anti-trust rules. The commission said its investigation concerned unilateral behaviour by Servier and agreements which might have blocked the entry of generic perindopril, a cardio-vascular medicine, originally developed by Les Laboratoires Servier, into the European Economic Area.